Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 June 2021 Photo Supplied
Carmien Tolmie
Dr Carmien Tolmie says being involved in the Global Challenges Research Fund (GCRF) START grant over the past three years has made a very concrete contribution to her career as a young scientist.

Dr Carmien Tolmie – Lecturer in the Department of Microbiology and Biochemistry at the University of the Free State (UFS) – is one of 30 postdoctoral research assistants in the United Kingdom and Africa who have benefited from the £3,7 M Global Challenges Research Fund (GCRF) START grant over the past three years. The grant was made available by the Science and Technology Facilities Council (STFC) in support of the Synchrotron Techniques for African Research and Technology (START) programme. The STFC is based in the United Kingdom.

The grant seeks to build partnerships between world-leading scientists in Africa and the UK who are working on research using synchrotron science. Forming part of this collaboration is the UK’s national synchrotron, Diamond Light Source (Diamond). The synchrotron, one of about 70 in the world, can be explained as a large machine, almost the size of a football field, which accelerates electrons to nearly the speed of light. According to Diamond, these fast-moving electrons produce very bright light, called synchrotron light. Scientists can use this light to study minute matter such as atoms and molecules.

 

Celebrating a new generation of scientists

On 7 June 2021, GCRF START celebrated its successes of the past years via a virtual event, including the new generation of scientists they trained. Diamond Light Source (Diamond) hosted the event.

In a statement issued by Diamond Light Source, Dr Tolmie was said to be one of the rising stars in the newly emerging Structural Biology network in South Africa. The statement reads that Dr Tolmie has made great strides with biocatalysis, investigating enzymes as drug targets for fungal infectious diseases that claim many lives, especially among immunocompromised patients.

Dr Tolmie claims that the workings of the natural world have always interested her, especially how it can be used to sustainably improve human health and agriculture. Observing some of the health challenges in Africa motivated her to take the opportunity to work with Prof Dirk Opperman, Associate Professor in the UFS Department of Microbiology and Biochemistry. Prof Opperman is a GCRF START co-investigator in the UFS Biocatalysis and Structural Biology research group, working on various bacterial and fungal enzymes.

Focusing on structural biology, Dr Tolmie is also working on drug discovery projects to find a sustainable solution through novel antifungal drugs.

To conduct the research that can improve the health of so many people suffering from infectious fungal diseases that can be serious, especially for immunocompromised patients living with HIV/Aids, recipients of organ transplants, patients undergoing chemotherapy and many more, Dr Tolmie will be using the drug discovery method of X-ray crystallographic fragment screening at Diamond Light Source (Diamond). “I was introduced to the concept and power of fragment screening techniques during GCRF START meetings,” says Dr Tolmie.

A research visit to Diamond Light Source in the UK in 2019, where she learned more about the experimental workflow of XChem and the i04-1 beamline, also inspired her to embark on XChem projects for antifungal drug discovery.

 

Exposed to cutting-edge scientific techniques

She attributes her recent appointment as lecturer to the mentoring and training she received through the GCRF START grant, which also funded a secondment to Diamond and the University of Oxford, exposing her to cutting-edge scientific techniques such as XChem fragment screening.

Prof Chris Nicklin, Science Group Leader and Principal Investigator in the GCRF START grant programme, says by providing the new generation of synchrotron users with access to world-class equipment and investing in their skills and capacity, research in the UK and Africa has been enriched and deepened.

“Being involved in the START grant has made a very concrete contribution to my career as a young scientist. GCRF START has also exposed me to many esteemed international scientists and facilities,” says Dr Tolmie.

Specifically alluding to the research that Dr Tolmie is working on, Dr Gwyndaf Evans, START Life Sciences Principal Investigator and principal beamline scientist on Diamond’s VMXm beamline, says: “It has been rewarding to see the relatively modest investment of time and money have such a major impact on the sustainability of research expertise, on the development of careers in Africa, on access to large-scale facilities around the world, and on the nurturing of collaborations and networks in South Africa.”

He continues: “In structural biology, there have been valuable exchanges and collaborations, especially XChem laying the foundations for drug discovery work. START is the beginning of embedding the structural research culture in South Africa and other groups around the world. We look forward to what the future holds.”

Dr Tolmie, who completed her BSc degree in Molecular Biology and Biotechnology at Stellenbosch University, completed her postgraduate studies (BSc Honours degree, MSc, and PhD) at the UFS.

News Archive

HIV Cure – Just another fantasy?
2016-07-27

Description: HIV Cure – Just another fantasy? Tags: HIV Cure – Just another fantasy?

Dr Dominique Goedhals, Prof John Frater,
Dr Thabiso Mofokeng and Dr Jacob Jansen van Vuuren,
attended the lecture. Prof Frater has been working in
collaboration with the UFS Department of Internal
Medicine on HIV resistance and HIV immunology
since 2007.

Photo: Nonsindiso Qwabe

Twenty-years ago, after a person had been diagnosed with HIV, their lifespan did not exceed three years, but thanks to the success of antiretroviral therapy programmes, life expectancy has risen by an average of ten years. However, is antiretroviral therapy always going to be for life? This is the societal issue that Professor John Frater, addressed in his talk at the University of the Free State. He is an MRC Senior Clinical Fellow, Associate Professor and Honorary Consultant Physician in Infectious Diseases at  Oxford University.

Antiretroviral medicine therapeutic

The discovery of antiretroviral therapy - the use of HIV medicines to treat the virus - has had a positive effect on the health and well-being of people living with it, improving their quality of life. Unfortunately, if treatment is stopped, HIV rebounds to the detriment of the patient. Now, research has shown that some patients, who are treated soon after being infected by HIV, may go off treatment for prolonged periods. Work is being done to predict who will be able to stop treatment.

“The difference made by starting treatment earlier is enormous. Delaying treatment is denying yourself the right to health,” Professor Frater says. However, this does not mean that the virus is cured. “A person can live for ten years without being on HIV treatment, but is that enough?” he went on to ask.

Healthy lifestyles encouraged

The National Department of Health will adopt a test and treat immediately strategy later this year to improve patient health and curb the spread of HIV. ,This is another reason why everybody should know their status and start treatment as soon as possible.

Search for a cure continues

More research is being conducted to establish whether HIV can be eradicated. Remission gives hope that a permanent cure may be found eventually. “Will a cure for HIV ever be found? Time will tell,” he concluded.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept